Trending...
- Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
- Wilson Venture Capital to Launch News Organization; Will Name Trevor Wilson CEO
- Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth
~ Congruence Therapeutics, a biotechnology company focused on developing small molecule correctors to rescue aberrant protein function, has announced their participation in the International Congress of Parkinson's Disease and Movement Disorders 2024 Meeting. The event will take place from September 27th to October 1st, 2024 in Philadelphia, PA.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
- netElastic Announces vBNG And CGNAT 2.0 General Availability
- Postmortem Pathology Highlights Private Autopsy Options for Las Vegas Families During Summer Months
- Postmortem Pathology Offers Sacramento Families Independent Answers on a Short Timeline
- Philly ECM Programming Announces Mobile Module Programming for Philadelphia Repair Shops
- NEW Three Fully Furnished Single-Family Model Homes at Heritage at South Brunswick
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
0 Comments
Latest on The PennZone
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Phoenix
- SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia
- BetQL Brings Data Driven 5 Star Betting Insights to the Everyday Sports Bettor
- Sky Quarry's Big Turning Point: CEO Marcus Laun Outlines the Next Phase for N A S D A Q: SKYQ
- Hunter Is Releasing New Music For The Holidays!
- Tixpool.com - Naija Premier Event Reseller
- Work 365 Expands Distributor Integrations with Companial for Microsoft Partners
- ClassicCarJobs.us Launches Automotive Career Marketplace for Specialty Shops
- Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity
- Dutch Mill Bulbs Launches Pink Ribbon Tulip Fundraise ~ National Breast Cancer Foundation, Inc.®
- SecureMaine 2026 is Here -- Thursday October 8th!
- Bluestone Laundromat Makes a Difference in the Archbald Community
- HW Foundation Opens Nominations for Inaugural 50 Under 50 in AI; Deadline Oct. 16
- Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
- ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
- BJJ App mmaGPT Expands Academy Program to Support Jiu-Jitsu Instructors with AI Technique Coaching
- Ten Ten Ten Announces Maximizing Clinical Operations
- Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth
- CardsNearby Launches Free Nationwide Directory of Card Shows and Local Card Shops for Collectors
- American Garden Rose Selections™ Announces 2027 Winners